Howe & Rusling’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8M | Sell |
42,193
-10,989
| -21% | -$2.07M | 0.46% | 65 |
|
|
2026
Q1 | $10.5M | Buy |
+53,182
| New | +$10.3M | 0.68% | 44 |
|
|
2025
Q4 | – | Sell |
-58,797
| Closed | -$9.02M | – | 480 |
|
|
2025
Q3 | $9.02M | Buy |
58,797
+204
| +0.3% | +$30.9K | 0.62% | 51 |
|
|
2025
Q2 | $8.19M | Sell |
58,593
-1,963
| -3% | -$275K | 0.6% | 49 |
|
|
2025
Q1 | $8.9M | Sell |
60,556
-17,677
| -23% | -$2.56M | 0.75% | 41 |
|
|
2024
Q4 | $10.3M | Buy |
78,233
+18,327
| +31% | +$2.57M | 0.88% | 31 |
|
|
2024
Q3 | $9.33M | Sell |
59,906
-14,892
| -20% | -$2.4M | 0.8% | 36 |
|
|
2024
Q2 | $11.7M | Sell |
74,798
-5,931
| -7% | -$892K | 1.06% | 28 |
|
|
2024
Q1 | $10.9M | Buy |
80,729
+2,481
| +3% | +$329K | 1.05% | 30 |
|
|
2023
Q4 | $10.5M | Buy |
78,248
+14,141
| +22% | +$1.84M | 1.12% | 30 |
|
|
2023
Q3 | $8.68M | Sell |
64,107
-267
| -0.4% | -$36.5K | 1.02% | 35 |
|
|
2023
Q2 | $9.21M | Sell |
64,374
-10,428
| -14% | -$1.53M | 1.03% | 32 |
|
|
2023
Q1 | $10.4M | Buy |
74,802
+1,261
| +2% | +$170K | 1.24% | 28 |
|
|
2022
Q4 | $9.97M | Buy |
73,541
+2,415
| +3% | +$303K | 1.25% | 27 |
|
|
2022
Q3 | $7.8M | Buy |
71,126
+35,929
| +102% | +$4.56M | 1.04% | 33 |
|
|
2022
Q2 | $4.65M | Buy |
+35,197
| New | +$4.62M | 0.59% | 58 |
|
|
2020
Q4 | – | Sell |
-55
| Closed | -$6K | – | 933 |
|
|
2020
Q3 | $6K | Buy |
+55
| New | +$6.12K | ﹤0.01% | 511 |
|
|
2019
Q2 | – | Sell |
-142
| Closed | -$11K | – | 811 |
|
|
2019
Q1 | $11K | Buy |
+142
| New | +$11.2K | ﹤0.01% | 432 |
|
|
2017
Q4 | – | Sell |
-859
| Closed | -$58K | – | 840 |
|
|
2017
Q3 | $58K | Buy |
859
+523
| +156% | +$33K | 0.01% | 288 |
|
|
2017
Q2 | $23K | Buy |
336
+275
| +451% | +$18K | ﹤0.01% | 357 |
|
|
2017
Q1 | $4K | Hold |
61
| – | – | ﹤0.01% | 694 |
|
|
2016
Q4 | $3K | Sell |
61
-179
| -75% | -$10.2K | ﹤0.01% | 765 |
|
|
2016
Q3 | $16K | Sell |
240
-58
| -19% | -$3.79K | ﹤0.01% | 410 |
|
|
2016
Q2 | $18K | Hold |
298
| – | – | ﹤0.01% | 367 |
|
|
2016
Q1 | $17K | Hold |
298
| – | – | ﹤0.01% | 426 |
|
|
2015
Q4 | $20K | Buy |
+298
| New | +$19.5K | ﹤0.01% | 382 |
|
|
2013
Q3 | – | Sell |
-47
| Closed | -$2K | – | 877 |
|
|
2013
Q2 | $2K | Buy |
+47
| New | +$2.39K | ﹤0.01% | 799 |
|
Other funds holding AZN
EP
IA
Howe & Rusling's AZN Position: Q2 2026 in Review
Howe & Rusling reduced its AstraZeneca (AZN) stake by 21% in Q2 2026, selling an estimated $2.07M and leaving 42,193 shares worth $8M. The position accounts for 0.46% of the portfolio, ranked #65.
Howe & Rusling first reported a position in AZN in Q2 2013 and has held it in 27 quarters since. The position peaked at $11.7M in Q2 2024. 1,505 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Howe & Rusling held 42,193 shares of AstraZeneca worth $8M as of Q2 2026.
- Howe & Rusling sold 10,989 AstraZeneca shares in Q2 2026, an estimated $2.07M.
- AstraZeneca made up 0.46% of Howe & Rusling's portfolio in Q2 2026, its #65 holding.
- Howe & Rusling first reported a position in AstraZeneca in Q2 2013 and has held it in 27 quarters since.
- Howe & Rusling's AstraZeneca position peaked at $11.7M in Q2 2024.
- 1,505 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Howe & Rusling's 13F filing for Q2 2026, filed 10 Aug 2026.